Johan van der Vlag and Tom Nijenhuis, theme Renal disorders, received this grant for their joint research project “Targeting a novel paracrine signaling pathway between glomerular endothelium and podocytes to treat glomerular injury”.
In patients with rare kidney filter (glomerular) disorders, glomerular injury leads to urinary protein leakage and chronic kidney disease (CKD). Novel therapies to treat glomerular disease or the ensuing progressive CKD have not emerged during the last decade. Thus, there is an unmet need for novel treatment targets, which can be translated into clinically applicable therapy at short term.It is increasingly recognized that paracrine signaling between glomerular endothelial cells and podocytes is crucial to glomerular integrity. Based on preliminary data from their laboratory, Van der Vlag and Nijenhuis hypothesized that nitric oxide (NO) produced by the endothelium activates a podocyte signaling pathway crucial to maintain podocyte viability. This novel paracrine glomerular endothelium-to-podocyte pathway could be therapeutically targeted by repurposing sGC stimulators/activators like Riociguat®.
Johan van der Vlag heads the Nephrology Research Laboratory and, fueled by clinical research questions, focuses on glomerular diseases and (transplantation) immunology. Tom Nijenhuis, internist-nephrologist, specializes in rare kidney disorders.
Related news items
BCG vaccine is safe with no increased risk of COVID-19 symptoms says Mihai Netea11 August 2020
The BCG vaccine has a general stimulatory effect on the immune system and is therefore effective against multiple infectious diseases - possibly also against COVID-19.read more
650,000 Euro funding for research into the phasing out of medication for leukaemia patients30 July 2020
With a 650,000 euro funding from ZonMw, researchers from the Haematology and Pharmacy departments can develop a medication phasing out strategy for patients with chronic myeloid leukaemia. This strategy will be tested in practice.read more
Increased role of patients after bowel cancer treatment30 July 2020
Approximately 14,000 patients get colorectal cancer every year. Almost all patients are operated on and monitored afterwards (follow-up). In 2019 Radboudumc started a new approach to follow-up research after the treatment of stage II/III colorectal cancer.read more
ERC Proof of Concept grant received by Ronald van Rij30 July 2020
Ronald van Rij, theme Infectious diseases and global health, received an ERC (European Research Council) Proof of Concept grant of 150,000 euros, in order to make arbovirus vaccines even safer.read more
Testing medical mouth masks Developed in the Netherlands30 July 2020
Auping and AFPRO developed medical mouth caps which were tested by Integrative Physiology. The results were shared with the producing companies.read more